Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carine Giovannangeli is active.

Publication


Featured researches published by Carine Giovannangeli.


Nature Structural & Molecular Biology | 2011

Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication

Koji Nakanishi; Francesca Cavallo; Loïc Perrouault; Carine Giovannangeli; Mary Ellen Moynahan; Marco Barchi; Erika Brunet; Maria Jasin

Homologous recombination (also termed homology-directed repair, HDR) is a major pathway for the repair of DNA interstrand cross-links (ICLs) in mammalian cells. Cells from individuals with Fanconi anemia (FA) are characterized by extreme ICL sensitivity, but their reported defect in HDR is mild. Here we examined ICL-induced HDR using a GFP reporter and observed a profound defect in ICL-induced HDR in FA cells, but only when the reporter could replicate.


Nucleic Acids Research | 2005

Stable transmission of targeted gene modification using single-stranded oligonucleotides with flanking LNAs

Charlotte Andrieu-Soler; Mariana Casas; Anne-Marie Faussat; Christelle Gandolphe; M. Doat; Denis Tempé; Carine Giovannangeli; Francine Behar-Cohen; Jean-Paul Concordet

Targeted mutagenesis directed by oligonucleotides (ONs) is a promising method for manipulating the genome in higher eukaryotes. In this study, we have compared gene editing by different ONs on two new target sequences, the eBFP and the rd1 mutant photoreceptor βPDE cDNAs, which were integrated as single copy transgenes at the same genomic site in 293T cells. Interestingly, antisense ONs were superior to sense ONs for one target only, showing that target sequence can by itself impart strand-bias in gene editing. The most efficient ONs were short 25 nt ONs with flanking locked nucleic acids (LNAs), a chemistry that had only been tested for targeted nucleotide mutagenesis in yeast, and 25 nt ONs with phosphorothioate linkages. We showed that LNA-modified ONs mediate dose-dependent target modification and analyzed the importance of LNA position and content. Importantly, when using ONs with flanking LNAs, targeted gene modification was stably transmitted during cell division, which allowed reliable cloning of modified cells, a feature essential for further applications in functional genomics and gene therapy. Finally, we showed that ONs with flanking LNAs aimed at correcting the rd1 stop mutation could promote survival of photoreceptors in retinas of rd1 mutant mice, suggesting that they are also active in vivo.


Proceedings of the National Academy of Sciences of the United States of America | 2008

Triplex-forming oligonucleotide–orthophenanthroline conjugates for efficient targeted genome modification

Fabio Cannata; Erika Brunet; Loïc Perrouault; Victoria Roig; Slimane Ait-Si-Ali; Ulysse Asseline; Jean-Paul Concordet; Carine Giovannangeli

The inefficiency of gene modification by homologous recombination can be overcome by the introduction of a double-strand break (DSB) in the target. Engineering the endonucleases needed, however, remains a challenging task that limits widespread application of nuclease-driven gene modification. We report here that conjugates of orthophenanthroline (OP), a DNA cleaving molecule, and triplex-forming oligonucleotides (TFOs), known to bind specific DNA sequences, are synthetic nucleases efficient at stimulating targeted genome modification. We show that in cultured cells, OP-TFO conjugates induce targeted DSBs. An OP-TFO with a unique target was highly efficient, and mutations at the target site were found in ≈10% of treated cells, including small deletions most likely introduced during DSB repair by nonhomologous end joining. Importantly, we found that when homologous donor DNA was cotransfected, targeted gene modification took place in >1.5% of treated cells. Because triplex-forming sequences are frequent in human and mouse genes, OP-TFO conjugates therefore constitute an important class of site-specific nucleases for targeted gene modification. Harnessing DNA-damaging molecules to predetermined genomic sites, as achieved here, should also provide inroads into mechanisms of DNA repair and cancer.


Nature Biotechnology | 2000

Triplex technology takes off.

Carine Giovannangeli; Claude Helene

teins for the presence of recombinant viruses that could be grown and amplified after ultracentrifugation. They were able to isolate several virus clones containing recombinant envelope proteins with elements from three of the five different parent envelope genes. Furthermore, they demonstrate that, unlike virus preparations containing the parent envelope proteins, the isolated recombinant viruses could be concentrated to reasonably high titers (106–107 infectious units/ ml or more) by ultracentrifugation. Although these titers are not yet near those of the VSV-G pseudotypes, they are impressive for what is surely still an unoptimized system. The described shuffling method has therefore produced retroviruses with at least two new phenotypes: a new tropism and an enhanced stability to ultracentrifugation. There are almost certainly many more altered phenotypes still lurking in the library, waiting to be selected for. The impressive lesson from these studies—a lesson that we have learned from other systems—that combinatorial libraries and selection of chimeric molecules can be more useful than “rational” vector design for the rapid identification of molecules with desired new properties. There is little likelihood that these recombinants could have been designed nearly as easily through the more traditional approach of first defining the structure–function relationships of the envelope or other viral proteins and using that knowledge to design recombinant molecules from first principles. Nature is far better at virus design than are most virologists, and the methods of in vitro recombination and selection of the desired phenotype after in vitro evolution will be extremely useful


Multiple Sclerosis Journal | 2018

The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination

Abdelkrim Mannioui; Quentin Vauzanges; Jean Baptiste Fini; Esther Henriet; Somya Sekizar; Loris Azoyan; Jean-Léon Thomas; David Du Pasquier; Carine Giovannangeli; Barbara A. Demeneix; Catherine Lubetzki; Bernard Zalc

Background: In multiple sclerosis, development of screening tools for remyelination-promoting molecules is timely. Objective: A Xenopus transgenic line allowing conditional ablation of myelinating oligodendrocytes has been adapted for in vivo screening of remyelination-favoring molecules. Methods: In this transgenic, the green fluorescent protein reporter is fused to E. coli nitroreductase and expressed specifically in myelinating oligodendrocytes. Nitroreductase converts the innocuous pro-drug metronidazole to a cytotoxin. Spontaneous remyelination occurs after metronidazole-induced demyelinating responses. As tadpoles are transparent, these events can be monitored in vivo and quantified. At the end of metronidazole-induced demyelination, tadpoles were screened in water containing the compounds tested. After 72u2009h, remyelination was assayed by counting numbers of oligodendrocytes per optic nerve. Results: Among a battery of molecules tested, siponimod, a dual agonist of sphingosine-1-phosphate receptor 1 and 5, was among the most efficient favoring remyelination. Crispr/cas9 gene editing showed that the promyelinating effect of siponimod involves the sphingosine-1-phosphate receptor 5. Conclusion: This Xenopus transgenic line constitutes a simple in vivo screening platform for myelin repair therapeutics. We validated several known promyelinating compounds and demonstrated that the strong remyelinating efficacy of siponimod implicates the sphingosine-1-phosphate receptor 5.


Proceedings of the National Academy of Sciences of the United States of America | 1997

Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target

Carine Giovannangeli; Silvia Diviacco; Valérie Labrousse; Sergei M. Gryaznov; Pierre Charneau; Claude Helene


Antisense & Nucleic Acid Drug Development | 1997

Progress in developments of triplex-based strategies.

Carine Giovannangeli; Claude Helene


Journal of the American Chemical Society | 1991

Single-stranded DNA as a target for triple-helix formation

Carine Giovannangeli; Thérèse Montenay-Garestier; Michel Rougée; Marcel Chassignol; Nguyen T. Thuong; Claude Helene


Nucleic Acids Research | 1992

Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation

Carine Giovannangeli; Nguyen T. Thuong; Claude Helene


Proceedings of the National Academy of Sciences of the United States of America | 2000

Unambiguous demonstration of triple-helix-directed gene modification

François-Xavier Barre; Slimane Ait-Si-Ali; Carine Giovannangeli; Richard Luis; Philippe Robin; Linda L. Pritchard; Claude Helene; Annick Harel-Bellan

Collaboration


Dive into the Carine Giovannangeli's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kristell Lazou

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Mathilde Bonnet-Duquennoy

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Robin Kurfurst

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Annick Harel-Bellan

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

François-Xavier Barre

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Slimane Ait-Si-Ali

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

Victoria Roig

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jesper Wengel

University of Southern Denmark

View shared research outputs
Researchain Logo
Decentralizing Knowledge